FR2349330B1 - - Google Patents

Info

Publication number
FR2349330B1
FR2349330B1 FR7612708A FR7612708A FR2349330B1 FR 2349330 B1 FR2349330 B1 FR 2349330B1 FR 7612708 A FR7612708 A FR 7612708A FR 7612708 A FR7612708 A FR 7612708A FR 2349330 B1 FR2349330 B1 FR 2349330B1
Authority
FR
France
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
FR7612708A
Other versions
FR2349330A1 (fr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SAVINI EMILE
Original Assignee
SAVINI EMILE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SAVINI EMILE filed Critical SAVINI EMILE
Priority to FR7612708A priority Critical patent/FR2349330A1/fr
Publication of FR2349330A1 publication Critical patent/FR2349330A1/fr
Application granted granted Critical
Publication of FR2349330B1 publication Critical patent/FR2349330B1/fr
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
FR7612708A 1976-04-29 1976-04-29 Composition destinee au traitement des hyperlipidemies Granted FR2349330A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FR7612708A FR2349330A1 (fr) 1976-04-29 1976-04-29 Composition destinee au traitement des hyperlipidemies

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR7612708A FR2349330A1 (fr) 1976-04-29 1976-04-29 Composition destinee au traitement des hyperlipidemies

Publications (2)

Publication Number Publication Date
FR2349330A1 FR2349330A1 (fr) 1977-11-25
FR2349330B1 true FR2349330B1 (fr) 1978-08-25

Family

ID=9172447

Family Applications (1)

Application Number Title Priority Date Filing Date
FR7612708A Granted FR2349330A1 (fr) 1976-04-29 1976-04-29 Composition destinee au traitement des hyperlipidemies

Country Status (1)

Country Link
FR (1) FR2349330A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3705549A1 (de) * 1987-02-18 1988-09-01 Ulrich Speck Verwendung von pyridoxin-derivaten bei der prophylaxe und therapie von hyperlipidaemien und atherosklerose
US6228858B1 (en) 1995-09-12 2001-05-08 University Of Kansas Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US6716858B1 (en) 1995-08-28 2004-04-06 Kansas University Medical Center Methods for inhibiting diabetic complications
US6740668B1 (en) 1995-08-28 2004-05-25 Kansas University Medical Center Methods for inhibiting diabetic complications
US6750209B1 (en) 1995-09-12 2004-06-15 Kansas University Medical Center Advanced glycation end-product intermediaries and post-amadori inhibition
US5744451A (en) 1995-09-12 1998-04-28 Warner-Lambert Company N-substituted glutamic acid derivatives with interleukin-1 β converting enzyme inhibitory activity
US6730686B1 (en) 1995-09-12 2004-05-04 Kansas University Medical Center Methods for inhibiting oxidative modification of proteins
US7030146B2 (en) 1996-09-10 2006-04-18 University Of South Carolina Methods for treating diabetic neuropathy
WO2000021516A2 (fr) * 1998-10-14 2000-04-20 Kansas University Medical Center Research Institute, Inc. Procedes destines a empecher des complications diabetiques
WO2000023063A2 (fr) * 1998-10-22 2000-04-27 University Of South Carolina Procedes pour inhiber les complications diabetiques
JP4680775B2 (ja) * 2003-10-01 2011-05-11 第一ファインケミカル株式会社 安定なビタミンｂ６誘導体
JP2008526783A (ja) * 2005-01-05 2008-07-24 メディキュア・インターナショナル・インコーポレーテッド トリグリセリドレベルを調節するための化合物及び方法

Also Published As

Publication number Publication date
FR2349330A1 (fr) 1977-11-25

Similar Documents

Publication Publication Date Title
JPS5644461B2 (fr)
DE2710070C2 (fr)
CH637799GA3 (fr)
FR2349330B1 (fr)
DE2658971C2 (fr)
FR2410584B2 (fr)
DE2614307C2 (fr)
FR2369902B1 (fr)
DE2659025C3 (fr)
DE2634342C2 (fr)
JPS5525260B2 (fr)
DE2601935C2 (fr)
JPS5615128B2 (fr)
JPS5360356U (fr)
JPS52153448U (fr)
JPS568628B2 (fr)
JPS5516803B2 (fr)
JPS5354387U (fr)
JPS52145852U (fr)
JPS52119494U (fr)
JPS52153583U (fr)
CS177442B1 (fr)
JPS5320704U (fr)
JPS535328U (fr)
CS175519B1 (fr)

Legal Events

Date Code Title Description
ST Notification of lapse